Frontlight ResearchEarly access
CompletedNo phase
Myopia Control With a Innovative Spectacle Lens
Key facts
- Who runs it
- Essilor International
- Where
- Boston, Chicago, Houston, Longwood, New York, Pittsburg, Pittsburgh, San Diego, and Vestal, United StatesSee the 9 sites
- Trial code
- Status
- Completed
- People taking part
- 159 people enrolled
- Started
- 29 Dec 2021
- Ended
- 20 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- innovative myopia control spectacle lens
- Single vision spectacle lens
- Record updated
- 22 December 2025
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Equal to or greater than 6 years and not older than 12 years at time of informed consent and assent
- Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.50 D in each eye
- Astigmatism, if present, of not more than 1.50 D
- Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D
- Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
- Agree to wear spectacles for ≥10 hours/day at least 6 days/week
- Willingness and ability to participate in trial for 3 years and attend scheduled visits
Who cannot take part
- Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state
- History of myopia control intervention (e.g., atropine, orthokeratology, multifocal contact lenses, etc.)
- Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down's syndrome, etc.)
- Strabismus by cover test at near or distance wearing correction
- Amblyopia
- Current or anticipated use of growth hormones
- Participation in any clinical study within 30 days of the Baseline visit
Where in United States
- New England College of OptometryBoston, United States
- Illinois College of OptometryChicago, United States
- Mann Eye InstituteHouston, United States
- Sabal Eye CareLongwood, United States
- SUNY College of OptometryNew York, United States
- Kannarr Eye CarePittsburg, United States
- UPMC Children's Hospital of PittsburghPittsburgh, United States
- Scripps Poway OptometrySan Diego, United States
- Sacco Eye GroupVestal, United States
About the trial
What the trial wants to find out
The purpose of this study is to demonstrate that the test spectacle lens is safe and effective in slowing myopia progression in children.
The 2 groups in the trial
- Innovative myopia control spectacle lensTreatment being tested
- Single vision spectacle lensPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Evaluation of A Innovative Spectacle Lens in Slowing Myopia Progression
- Publications
- Record updated
- 22 December 2025